Evalstotug Biosimilar - Research Grade

Human

CTLA4

>1mg/ml

IgG1 - kappa

CHO Cells

Ipilimumab Biosimilar - Research Grade (ICH4025), Tremelimumab Biosimilar - Research Grade (ICH5184), Botensilimab Biosimilar - Research Grade (ICH5412), Firastotug Biosimilar - Research Grade (ICH5550), Gotistobart Biosimilar - Research Grade (ICH5583), Muzastotug Biosimilar - Research Grade (ICH5696), Nurulimab Biosimilar - Research Grade (ICH5717), Quavonlimab Biosimilar - Research Grade (ICH5794), Sovipostobart Biosimilar - Research Grade (ICH5879), Tazlestobart Biosimilar - Research Grade (ICH5904), Tuvonralimab Biosimilar - Research Grade (ICH5951), Vilastobart Biosimilar - Research Grade (ICH5979), Zalifrelimab Biosimilar - Research Grade (ICH5998)

https://www.imgt.org/mAb-DB/

ICH3002

P16410

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-CTLA-4 antibody evalstotug, produced for research use only and not intended for human or veterinary use. It is a human IgG1-kappa immunoglobulin engineered to bind the human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, UniProt P16410), making it a useful tool reagent for interrogating the CTLA-4 immune checkpoint axis in a controlled setting. Researchers use analogs like this as consistent, well-characterized binders for in-vitro receptor-blocking assays, as reference or benchmarking controls against other anti-CTLA-4 clones, for ADCC/effector-function and antibody-engineering workflows, and in preclinical target-validation studies. It is supplied at low endotoxin levels (research grade typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities to support assay development, screening campaigns, and scale-dependent experiments. Because it is an analog built around the CTLA-4 target rather than the clinical drug substance, it should be treated strictly as a laboratory research reagent. CTLA-4 (cytotoxic T-lymphocyte-associated protein 4, CD152; UniProt P16410) is an inhibitory immune checkpoint receptor expressed on activated conventional T cells and constitutively on regulatory T cells (Tregs). It is a member of the immunoglobulin superfamily and shares the B7 ligands CD80 (B7-1) and CD86 (B7-2) with the costimulatory receptor CD28, but binds them with markedly higher affinity. By outcompeting CD28 for these ligands and by physically removing B7 molecules from antigen-presenting cells via trans-endocytosis, CTLA-4 dampens the costimulatory signals required for full T-cell activation. This delivers a critical negative regulatory brake that maintains peripheral tolerance and limits autoimmunity. Because CTLA-4 blockade can release this brake and enhance antitumor T-cell responses, the receptor is a central node in cancer immunotherapy and a widely studied checkpoint target.

Cytotoxic T-lymphocyte-associated antigen 4, Cytotoxic T-lymphocyte protein 4, CD152

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks